HIGHLIGHTS
- who: Ahmad Y. Abuhelwa from the University at Buffalo, United States have published the paper: C-reactive protein provides superior prognostic accuracy than the IMDC risk model in renal cell carcinoma treated with Atezolizumab/Bevacizumab, in the Journal: (JOURNAL)
- what: Using pooled data from two clinical trials, this study demonstrated that CRP is a strong prognostic marker for survival in patients with mRCC initiating atezolizumab ICI treatment. A potential study limitation is that the analysis was only focused on patients treated with atezolizumab plus bevacizumab. The focus of this paper was on using CRP as . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.